Pacer Advisors
ENTA icon

Pacer Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Pacer Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-798
Closed -$39K – 1452
2021
Q1 		$39K Sell
798
-366
-31% -$18.3K ﹤0.01% 1465
2020
Q4 		$49K Buy
1,164
+262
+29% +$11.5K ﹤0.01% 1419
2020
Q3 		$41K Buy
+902
New +$43.7K ﹤0.01% 1310
2019
Q4 		– Sell
-5,170
Closed -$311K – 1261
2019
Q3 		$311K Buy
5,170
+1,234
+31% +$91.7K 0.01% 1066
2019
Q2 		$332K Buy
+3,936
New +$354K 0.01% 1021
2018
Q4 		– Sell
-2,693
Closed -$230K – 700
2018
Q3 		$230K Buy
+2,693
New +$270K 0.01% 1003
2018
Q1 		– Sell
-450
Closed -$26K – 1065
2017
Q4 		$26K Buy
+450
New +$22.5K ﹤0.01% 1081

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Pacer Advisors's ENTA Position: Q2 2021 in Review

Pacer Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q2 2021, closing a stake of 798 shares — an estimated $39K sold.

Pacer Advisors first reported a position in ENTA in Q4 2017 and held it in 7 quarters. The position peaked at $332K in Q2 2019. 151 funds tracked by Wall St. Rank hold ENTA as of Q2 2021.

  • Pacer Advisors reported no remaining Enanta Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Pacer Advisors sold 798 Enanta Pharmaceuticals shares in Q2 2021, an estimated $39K.
  • Pacer Advisors first reported a position in Enanta Pharmaceuticals in Q4 2017 and held it in 7 quarters.
  • Pacer Advisors's Enanta Pharmaceuticals position peaked at $332K in Q2 2019.
  • 151 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.